Právní předpis byl sestaven k datu 19.12.2013.
Zobrazené znění právního předpisu je účinné od 25.12.2012 do 19.12.2013.
97
XXXXXXX
Xxxxxxxxxxxx zahraničních věcí,
xxxxxx xx xxxx x xxxxxxxx sdělení Xxxxxxxxxxxx xxxxxxxxxxxx xxxx x. 58/2007 Xx. x. s., x. 46/2008 Xx. x. x. x x. 47/2012 Sb. x. x. o Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxx, že dne 16. xxxxxxxxx 2011 xxxx xxxxxxxxx xxxxxxxxxx XXXXXX xxxxxxxx schválení xxxxxx znění Xxxxxxx X - Xxxxxxx xxxxxxxxxx látek a xxxxx - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx ve xxxxxx.1)
X xxxxx xxxxxx Xxxxxxx X xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx xxxxxxxxx.
Xxxx xxxxx Xxxxxxx I xxxxxxxxx x xxxxxxxx x xxxxxxx x xxxxxxx 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2012 x tímto dnem xxxxxxxxx x platnost x xxx Xxxxxx xxxxxxxxx. Xxxx vstupu xxxxxx xxxxx Xxxxxxx X v xxxxxxxx xxxxxxxx xxxxxx xxxxx Xxxxxxx I Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx xxxxxx xx 1. xxxxx 2011 x xxxxxxxxx xxx č. 47/2012 Sb. m. s.
Anglické xxxxx Přílohy I x její xxxxxxx xx českého xxxxxx xx xxxxxxxxx současně.
1) Xxxxxxxxxxx xxxxxx xxxxx dopingu xx xxxxxx přijatá xxx 19. xxxxx 2005 x Paříži xxxx vyhlášena xxx č. 58/2007 Sb. m. s.
XXXXXXXXXXX XXXXXX XXXXX XXXXXXX XX XXXXXX
Xxxxxxx X - Xxxxxx xxxxxxxxxx látek x xxxxx - Mezinárodní xxxxxxxx
Xxxxx, 1. xxxxx 2012
XXXXXX XXXXXXXXXX LÁTEK A XXXXX XXXXXXX XXX XXX 2012
XXXXXXX XXXXXXXXXXXXX KODEX
Platný xx 1. xxxxx 2012
Xxxxx xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxx xxxxxxx Xxxxxxxx xxxxx xxxxx xxxxxxxxxx xx "Xxxxxxxxxx látky" xxxxx xxxxx xx xxxxxx X1, X2, X4.4, S4.5 x X6(x) x Zakázaných xxxxx X1, X2 x X3.
LÁTKY X XXXXXX XXXXXXXX XXXXX (PŘI SOUTĚŽI X XXXX XXXXXX) |
XXXXXXXX LÁTKY
S0. XXXXXXXXXXX LÁTKY
Xxxxxxxxx xxxxxxxxxxxxx xxxxx, xxxxx xxxx xxxxxxxx x xxxxxxxxxxxxx xxxxxxx Seznamu x xxxx xxxxxxxx xxxxxxxxx xxx humánní xxxxxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxx zdravotnickým regulačním xxxxxx (např. xxxxxx x xxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx xxxxxxx xxxx xx xxxxxxxx xxxxxxxxxx, xxxxxxxxxx drogy, xxxxxxxxxxx xxxx), xx xxxxxxxx xxxxx.
X1. XXXXXXXXXX XXXXX
Xxxxxxxxxx xxxxx jsou xxxxxxxx.
1. XXXXXXXXXX ANABOLICKÉ XXXXXXXX (XXX):
(a) Xxxxxxxx* AAS, zahrnující:
1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3β,17β-xxxx); 1-androstendion (5α-xxxxxxx-1-xx-3,17-xxxx); bolandiol (xxxx-4-xx-3β,17β-xxxx); xxxxxxxxxx; xxxxxxxx; xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx); danazol (17α-ethynyl-17β-hydroxyandrost-4-eno[2,3-d]isoxazol); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17β-xx); xxxxxxxxxxx; ethylestrenol (19-xxx-17α-xxxxx-4-xx-17-xx); xxxxxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxxxxx[2,3-x]-xxxxxxx); xxxxxxxxx; 4-xxxxxxxxxxxxxxxxxx (4,17β-xxxxxxxxxxxxxxxx-4-xx-3-xx); kalusteron; xxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-hydroxy-17α-methylandrosta-1,4-dien-3-on); metenolon; xxxxxxxxxxx; xxxxxxxxxx (2α, 17α-xxxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); xxxxxxxxxxxxxx (17β-hydroxy-17α-methylestra-4,9-dien-3-on); xxxxxx-1-xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx); methylnortestosteron (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxxxx; xxxxxxxxxx (xxxxxxxxxxxxxxx (17β-hydroxy-17α-methylestra-4,9,11-trien-3-on); miboleron; xxxxxxxxx; 19-norandrostendion (xxxx-4-xx-3,17-xxxx); xxxxxxxxxx; norethandrolon; xxxxxxxxxxxx; xxxxxxxx; oxandrolon; xxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-hydroxy-5α-androstano [3,2-x]xxxxxxx); quinbolon; xxxxxxxxxx; xxxxxxxxx; 1-xxxxxxxxxxx (17β-xxxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxx (18α-xxxx-xxxxxx-4,9,11-xxxxx-17β-xx-3-xx); xxxxxxxxx x xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx účinky.
(b) Xxxxxxxxx** XXX, xxxxx xxxx podány xxxxxxxx:
Xxxxxxxxxxxxx (androst-5-en-3β,17β-diol), xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx), dihydrotestosteron, xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX), xxxxxxxxxxx x xxxxxx xxxxxxxxxx x isomery, ale xx x omezením xxxxx xx xx:
5α-xxxxxxxxx-3α,17α-xxxx | 5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx) |
5α-xxxxxxxxx-3α,17β-xxxx | |
5α-xxxxxxxxx-3β,17α-xxxx | xxx-xxxxxxxxxxxxxxxxxx |
5α-androstan-3β,17β-diol | epitestosteron |
xxxxxxx-4-xx-3α,17α-xxxx | 3α-xxxxxxx-5αxxxxxxxxx-17-xx |
androst-4-en-3α,17β-diol | 3β-xxxxxxx-5αxxxxxxxxx-17-xx |
xxxxxxx-5-xx-3β,17α-xxxx | 7α-hydroxy-DHEA |
xxxxxxx-5-xx-3α,17α-xxxx | 7β-xxxxxxx-XXXX |
xxxxxxx-5-xx-3α,17β-xxxX | 7-xxxx-XXXX |
xxxxxxx-5-xx-3β,17α-xxxx | 19-norandrosteron |
4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3β,17β-xxxx) | 19-xxxxxxxxxxxxxxxxx |
2. Xxxxxxx xxxxxxxxxx xxxxx, xxxxxxxxxx:
Xxxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxx, xxxxxxx, zilpaterol, ale xx x xxxxxxxx xxxxx xx xx.
Xxx účely xxxxxxx xxxx sekce: * "xxxxxxxx" xx vztahuje x xxxxx, xxxxxx xxxx xxxx normálně xxxxxxx xxxxxxxxxx xxxxxxxxx. ** "xxxxxxxxx " xx xxxxxxxx x xxxxx, kterou xxxx xxxx xxxxxxxxxx přirozeně. |
X2. XXXXXXXXX XXXXXXX, XXXXXXX XXXXXXX X XXXXXXXX XXXXX
Xxxxxxxxxxx látky x xxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxxxx:
1. Xxxxx xxxxxxxxxxx xxxxxxxxxxx (xxxx. xxxxxxxxxxxx (XXX), xxxxxxxxxxx (dEPO), xxxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx (XXX), xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx beta (XXXX), xxxxxxxxxxx /Xxxxxxxx/);
2. Xxxxxxxxxxxxxxxxxx (XX) x Xxxxxxxxxxxx xxxxxx (XX) x xxxx;
3. Xxxxxxxx;
4. Xxxxxxxxxxxxxx;
5. Xxxxxxx xxxxxx (GH), fibroblastové xxxxxxx faktory (XXXx), xxxxxxxxxxxx xxxxxxx xxxxxx (XXX), xxxxxxxx podobný xxxxxxx xxxxxx-1 (IGF-1), xxxxxxxxxx xxxxxxx faktory (XXX), xxxxxxx xxxxxx xxxxxxxx x krevních xxxxxxxx (PDGF) x xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx faktor (XXXX), xxxxxx xxxx xxxxxxxxx jiné xxxxxxx xxxxxxx xxxxxxxxxxx syntézu xxxx degradaci xxxxxxxx xxxxx, xxxxx x xxxxxx, krevní zásobení, xxxxxxx xxxxxxx, xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxx xxxxxxxxx xxxxxx;
x xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx účinky.
X3. XXXX2- XXXXXXXX
Xxxxxxx xxxx-2 agonisté (xxxxxx xxxx případných xxxxxxxxx xxxxxxx) xxxx zakázáni xxxxx salbutamolu (xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx), formoterolu (xxxxxxxxx 36 xxxxxxxxxx xx 24 hodin) x xxxxxxxxxxx xxxxx xxxx xxxxxx v xxxxxxxx x souladu x xxxxxxxxxxx xxxxxxxx xxxxxxx výrobce.
Xxxxxxxxxx xxxxxxxxxxx v xxxx x koncentraci xxxxx xxx 1000 xx/xx x přítomnost xxxxxxxxxxx x moči v xxxxxxxxxxx xxxxx než 30 xx/xx xxxxxx xxxxxxxxxx za xxxxxxxxx xxxxxxxxxxxx xxxxxxx, xxx xxxx xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx xxxxxxxxx neprokáže xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx studií, xx abnormální xxxxxxxx xxx xxxxxxxx xxxxxxxx xxxxxxxxxxxx inhalační dávky xxxxx než xxxx xxxxxxx maximum.
X4. XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
1. Xxxxxxxxxx xxxxxxxx, zahrnující:
Xxxxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (xxxxxxxxxxxxxxxxx), 4-xxxxxxxxx-3,6,17-xxxxx (6-oxo),exemestan, formestan, xxxxxxxx, testolacton, xxx xx s xxxxxxxx xxxxx na xx.
2. Selektivní xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxxxxx:
Xxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxx ne x omezením xxxxx xx ně.
3. Xxxxxxx xxxxxxxxxxxxxx xxxxx xxxxxxxxxx:
Xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, xxx xx x omezením xxxxx xx ně.
4. Xxxxx modifikující funkce xxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx ně.
5. Xxxxxxxxxxx xxxxxxxxxx: Xxxxxxxx xxxxx xxxxxxxxxx peroxizomovými xxxxxxxxxxxxx /Xxxxxxxxxx Xxxxxxxxxxxx Xxxxxxxxx Receptor δ (XXXXδ) agonists/ (xxxx. XX 1516) x Xxxxxxxx xxxxxxxxxxxxxxx xxx aktivované AMP x součinnosti x XXXX xxxxx /PPARδ-AMP-activated xxxxxxx xxxxxx (XXXX) xxxx xxxxxxxx/ (xxxx. XXXXX)
X5. DIURETIKA X XXXXXXX XXXXXXXXX XXXXX
Xxxxxxxxx látky xxxx xxxxxxxx. Zahrnují:
Xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxx. xxxxxxxx, xxxxxxxxxx xxxxxx xxxxxxxx, dextranu, xxxxxxxxxxxxxxxxxx x xxxxxxxxx), xxxxxxxxxx a xxxxx xxxxx x xxxxxxxxx xxxxxxxxxxxx účinky. Lokální xxxxxxxx xxxxxxxxxxxx xxx xxxxx xxxxxxxx není xxxxxxxx.
Diuretika xxxxxxxx:
Xxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, xxxxxxxx, kyselina etakrynová, xxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxx (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), xxxxxxxxxx a xxxxx xxxxx s xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx biologickými xxxxxx (xxxxx xxxxxxxxxxxx, xxxxxxxxx a xxxxxxxxx xxxxxx xxxxxxxxxxx x xxxxxxxxxxxx, xxxxx nejsou xxxxxxxx).
Xxx použití (Xxx Soutěži, případně Xxxx Soutěž) xxxxxxxxxxx xxxxxxxx xxxxx xx xxxxxxxxxx xxxxxxxx xxxxxxx (xx. xxxxxxxxxx, salbutamol, xxxxxx, xxxxx, xxxxxxx, xxxxxxxxxxxx x xxxxxxxxxxxxx) xx xxxxxxx s xxxxxxxxxx xxxx jinou xxxxxxxxx xxxxxx xx xxxxxxxxxx xxxxxxx xxxxxxxxxx Xxxxxxxxxxxx výjimky xx xxxx xxxxx navíc x té, která xxx xxxx xxxxxxx xx xxxxxxxxxx xxxx xxxxx maskovací xxxxx.
XXXXXXXX METODY
X1. XXXXXXXXX XXXXXXX KYSLÍKU
Xxxxxxxx xx xxxxxxxxxxx:
1. Krevní xxxxxx, xxxxxx xxxxxxx xxxxxxxxx, xxxxxxxxx nebo xxxxxxxxxxx xxxx nebo xxxxxxxxx xxxxxxx x xxx xxxxxxxxx produktů jakéhokoliv xxxxxx.
2. Xxxxx xxxxxxxxx spotřeby, xxxxxxx xxxx xxxxxxx xxxxxxx, xxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx (xxxx.xxxxxx xxxxxxxx xxxxxxxx xx xxxxxxxxxxx, xxxxxxxxxxxxxxxxxx hemoglobiny), xxxxxxxxxxxxxxxxxxx x xxxxxxxxxxx (XXX13), xxx xx s xxxxxxxx pouze xx xx. Xxxxxxxx xxxxxxx xxxxxxxx xxxx.
M2. XXXXXXXX X XXXXXXXXX XXXXXXXXXX
Xxxxxxxx je xxxxxxxxxxx:
1. Podvádění, xxxx xxxxx x xxxxxx, za účelem xxxxxxx integritu x xxxxxxxx Vzorků xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx xx xxxxxxxx. Xx xxxxxxxx xxxxxx x/xxxx xxxxxx (xxxx. xxxxxxxxxx) xxxx, xxx xx x xxxxxxxx xxxxx xx xx.
2. Xxxxxxxxxx xxxxxx a/nebo xxxxxxx xxxx xxx 50 xx xx 6 xxxxx xxxx xxxxxxxx xxxxx xxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxx xxxxxxxxxxxx zákroků xxxx klinických vyšetřovacích xxxxx.
3. Xxxxxxxx xxxxx, xxxxxxxxxx x xxxxxxxxx xxxxxxxxxxx množství xxxx xxxx xx xxxxxxxxx xxxxxxx xx xxxxxxxx.
X3. GENOVÝ XXXXXX
X xxxxxx xxxxxxxxxx xx xxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxx xxxxxxxxxxx:
1. Xxxxxxxx nukleových xxxxxxx xxxx xxxxxx xxxxxxxx;
2. Použití normálních xxxx xxxxxxxxx modifikovaných xxxxx;
XXXXX X METODY ZAKÁZANÉ XXX SOUTĚŽI |
Xxxxx kategorií SO xx X5 x X1 xx X3 xxxxxxxxx výše xxxx Xxx Xxxxxxx xxxxxxxx x následující xxxxxxx:
XXXXXXXX XXXXX
X6. XXXXXXXXXXX
Xxxxxxx xxxxxxxxxxx (xxxxxx xxxx xxxxxx xxxxxxxxxx optických xxxxxxx) xxxx xxxxxxxx, x xxxxxxxx xxxxxxxx xxxxxxxxx x xxxxxxx xxxxxx xxxxxxxx xxxxxxx a xxxxxxxxxxx zahrnutých do Xxxxxxxxxxxxxx xxxxxxxx pro xxx 2012*.
Xxxxxxxxxxx xxxxxxxx:
(x) Xxxxxxxxxxxx xxxxxxxxxxx:
Xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxx, fendimetrazin, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, fenmetrazin, xxxxxxxxxxx, xxxxxxxxx, 4-fenylpiracetam (xxxxxxxx), xxxxxxxxxx, xxxxxxxxxxx, xxxxxx, kropropamid, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, metamfetamin (x-), xxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxxxxxx, xxxxxxxx, modafinil, xxxxxxxxxxxxxx, x-xxxxxxxxxxxxxxx, xxxxxxxxxx, prolintan.
Xxxxxxxxxxxx, xxxxx xxxx xxxxxxxx xxxxxxx x xxxxx odstavci, je Xxxxxxxxxxx xxxxxx.
(x) Xxxxxxxxxx xxxxxxxxxxx (příklady):
Xxxxxxxxx**, katin***, xxxxxxx****, xxxxxxxx, xxxxxxxxx, fenbutrazát, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx, levmetamfetamin, xxxxxxxxxxxx, xxxxxxxxxxxx****, xxxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxx), niketamid, norfenefrin, xxxxxxxxx, xxxxxxxxx, parahydroxyamfetamin, xxxxxxx, xxxxxxxxxxx, propylhexedrin, xxxxxxxxxxxxx*****xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx x další xxxxx s xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx.
* Xxxxxxxxxxx xxxxx xxxxxxxx do Xxxxxxxxxxxxxx xxxxxxxx 2012 (xxxxxxxxx, xxxxxxxxxx, fenylpropanolamin, xxxxxx, xxxxxxx, xxxxxxxxx, xxxxxxxx) xxxxxx xxxxxxxxxx xx Xxxxxxxx xxxxx.
** Xxxxxxx xxxxxx xxxxxxxxxx (xxxx. xxxxx, xxxx xxxxxxxx) nebo xxxx xxxxxx xxxxxxxx s xxxxxxxxx anestetiky není xxxxxxxx.
*** Xxxxx xx zakázaný xxxxx xxx xxxxxxxxxxx xxxxx xxx 5 mikrogramů x 1 xx xxxx.
**** Efedrin x xxxxxxxxxxxxx xxxx xxxxxxxx xxx xxxxxxxxxxx xxxxx xxx 10 xxxxxxxxxx v 1 xx xxxx.
***** Xxxxxxxxxxxxx je zakázán, xxxxx xxxx koncentrace x moči xx xxxxx xxx 150 xxxxxxxxxx xx mililitr
X7. XXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
Xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx(xxxxxx), fentanyl x jeho xxxxxxxx, xxxxxxxxxxx, metadon, xxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx.
X8. KANABINOIDY
Xxxxxxxx (xxxx. xxxxx, xxxxxx x xxxxxxxxx) xxxx syntetický delta9tetrahydrokanabinol (XXX) x xxxxxxxxxxxxxx (xxxx. "Xxxxx" /xxxxxxxxxx XXX018, XXX073/ a XX-210) jsou xxxxxxxx.
X9. XXXXXXXXXXXXXXXXXXXX
Xxxxxxx xxxxxxxxxxxxxxxxxxxx xxxxxxxx xxxxxx, xxxxxxxx, xxxxxxxxxx xxxx xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxx.
XXXXX XXXXXXXX X XXXXXXXX XXXXXXXX |
P1. XXXXXXX
Xxxxxxx (xxxxxx) xx xxxxxxxx xxxxx Xxx Xxxxxxx x xxxxxxxxxxxxx sportech. Detekce xx xxxx provádět xxxxxxxx xxxxxxxx x/xxxx xxxxxxxx xxxx. Prahová xxxxxxx xxx porušeni xxxxxxxxxxx xxxxxxxx (xxxxxxxxxxxxx xxxxxxx) xx 0.10 x/x.
∙ Automobilový xxxxx (XXX)
∙ Xxxxxx (XXX)
∙ Xxxxxxx xxxxxx x xxxxxxxxxxxx(XXX)
∙ Lukostřelba (XXXX)
∙ Xxxxxxxxxxx xxxxx (XXX)
∙ Xxxxx motorismus (XXX)
X2. XXXX-XXXXXXXXX
Pokud xxxx xxxxx určeno, xxxx-xxxxxxxxx jsou xxxxxxxx xxxxx Xxx Xxxxxxx x následujících xxxxxxxx.
∙ Xxxxxxxxxxxx xxxxx (XXX)
∙ Xxxxxxxx (xxxxxxx xxxxxxxxxx) (XXXX)
∙ Xxxxx (FMB)
∙ Golf (IGF)
∙ Xxxxxxx a xxxxxxx (XXX)
∙ Xxxxxxx sporty x xxxxxxxxxxxx (XXX)
∙ Xxxxxxxxxxx (FITA, XXX) (xxxxxxxx také Mimo xxxxxx)
∙ Lyžování (XXX) - xxxxx xx xxxxxx x xxxxxxxxxxx lyžování-skoky x X-xxxxx,x xxxxxxxxx U-rampa x "big xxx"
∙ Xxxxxxxx x xxxxxxx sporty (XXXX)
∙ Střelba (XXXX, XXX) (zakázané také Xxxx soutěž)
∙ Xxxxx (XXX)
∙ Xxxxx xxxxxxxxxx (XxX)
Xxxx-xxxxxxxxx xxxxxxxx následující xxxxx:
Xxxxxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx, celiprolol, xxxxxxx, xxxxxxxxx, xxxxxxxxxx, labetalol, xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxxx, xxx xx x xxxxxxxx xxxxx na xx.
Informace
Xxxxxx xxxxxxx x. 97/2012 Xx. m. x. xxxxx účinnosti xxxx 25.12.2012.
Xxxxxx předpis x. 97/2012 Xx. x. x. xxx xxxxxx xxxxxxx xxxxxxxxx č. 98/2013 Sb. m. s. x účinností od 20.12.2013.
Xxxxx xxxxxxxxxxxx právních xxxxx xxxxxx xxxxxxxx předpisů x odkazech xxxx xxxxxxxxxxxxx, xxxxx xx xxxx xxxxxx xxxxxxxxx xxxxx xxxxx uvedeného xxxxxxxx xxxxxxxx.